Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Invest New Drugs. 2010 Oct 12;30(2):629–638. doi: 10.1007/s10637-010-9563-7

Figure 3.

Figure 3

Cytokine release vs. total and unbound flavopiridol. The relationship between cytokine release syndrome (CKRS) severity and total (A) or unbound (B) plasma flavopiridol at the end of the 4-hour infusion (C4.5hr) is displayed. Similar plots are displayed for AUC0–∞ calculated from total (C) or unbound (D) flavopiridol concentrations